MedTrace Logo

Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients

NCT01602198 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2017-02-28

Study results available
· View outcomes & findings →

Summary

The goal of this project is to determine if task-activated fMRI is sensitive to the central cholinergic deficit associated with Mild Cognitive Impairment.

Conditions

Interventions

DRUG

Exelon [rivastigmine] transdermal patch

Exelon patch 1/day for six months

DRUG

Placebo transdermal patch

Placebo transdermal patch 1/day for 6 months

Sponsors & Collaborators

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Stephen M Rao · The Cleveland Clinic

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01602198 on ClinicalTrials.gov